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Multimorbidity and polypharmacy are serious and prevalent issues, both lead to poor health outcomes such 
as readmission to hospital and adverse drug reactions. Diabetes and cardiovascular diseases are commonly 
comorbid conditions which often lead to patients with polypharmacy and multiple hospital admissions. 
Methods 
A prospective cohort study enrolled older diabetic patients with cardiovascular disease from a single tertiary 
care hospital. Demographic, clinical, psychologic, and pharmacological data were collected. Several 
assessments were applied to discharge medication lists. Univariate and multivariate analyses were performed 
to assess which factors were associated with time to readmission and readmission in 30-days. 
Results 
Of 100 participants 47% were readmitted during the study and 30% of those were within 30-days. 97% of 
participants had polypharmacy and median scores for the Beers Criteria and Anticholinergic Risk Scale were 
both 0. There were no significant differences between readmitted and not readmitted participants but 
associations between DASS stress (p=0.041) and confidence in medications (p˂0.001) with time to 
readmission were observed. 
Conclusion  
The population was biased to more complicated patients and although polypharmacy was highly prevalent, 
medications were largely appropriate and not associated with readmission rates. Noise surrounding the 
outcome measure of readmission may have contributed to a lack of expected results. Further research is 
required with a larger sample size and more heterogenous population to accurately assess the effects of 
polypharmacy.  
(223 words)  
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Assessment of factors affecting readmission and care integration in inpatients with diabetes and 
cardiovascular disease 
Introduction 
The ageing population is leading to higher rates of people living with multimorbidity or more than one 
chronic condition. In Australia, the prevalence of multimorbidity has been estimated at 37.1% which 
increased drastically to 83.2% in Australians aged ≥75.1 Multimorbidity is also associated with 
polypharmacy which is regularly defined as 5 or more regular medications.2, 3 Polypharmacy can lead to an 
increased risk of inappropriate medications, adverse drug reactions, hyperpolypharmacy (≥10 regular 
medications) and reduced compliance due to complex medication regimens.2, 4, 5 Polypharmacy and increased 
medication numbers have also been shown to be associated with readmission.6, 7  
 
Diabetes Mellitus and Cardiovascular Diseases are commonly comorbid conditions due to their similar 
pathological basis.8 In 2013 it was estimated that there was 382 million people with diabetes worldwide, 
which was projected to increase to 592 million by 2035.9 Research has shown 90% of patients with type 2 
diabetes have at least one other chronic condition; with hypertension in 66% and heart disease in 25% as the 
most common.3 Diabetics with comorbidities of cardiovascular diseases were shown to be twice as likely to 
have polypharmacy and were also associated with a higher risk of hospital admissions and health costs.10 
Furthermore polypharmacy due to diabetes has been found to be a risk factor for medication errors in 
hospital.11 
 
Multimorbidity is associated with high health care costs and admissions to hospital.12 Furthermore, research 
shows that diabetic patients and people with cardiovascular diseases have increased rates of readmission to 
hospital.13-16 However, increased health care expenditure and utilisation doesn’t always lead to better 
outcomes and care as many patients are still experiencing poor health outcomes.17 There is evidence for 30-
day readmission being associated with increased numbers of medications in older populations7 and 
readmission has been associated with both recent admissions and certain diabetes treatments in patients with 
diabetes hospitalised for cardiovascular disease.15 Readmission within 30-days tends to be the outcome of 
interest but chronic conditions need long term follow up as well.14, 15, 18, 19 It is clear that diabetes and 
cardiovascular disease are both prevalent and these conditions are place a large burden on health care 
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systems worldwide.20 Care integration aims to coordinate care between healthcare systems and often 
involves multidisciplinary interventions. There is evidence for the effectiveness of this in people with 
diabetes and cardiovascular diseases17. However, such interventions are expensive, and when given to groups 
with lower risk it can result in no benefit to the patient and therefore wasted time and resources.21 
 
Most prior research has been retrospective which provides useful and worthwhile information however limits 
the data and assessments which can be collected, and therefore, the conclusions drawn. This means there is 
still a gap in the knowledge about how to best coordinate the care for people with diabetes and 
cardiovascular disease and which factors contribute to outcomes such as readmission in people with both 
conditions. Understanding what leads to readmission in these individuals is paramount in order to effectively 
design and target care integration interventions to reduce them.  
 
Hypothesis 
It is hypothesised that polypharmacy is more important than demographical, physical, social, and 
psychological factors in assessing readmission in inpatients with cardiovascular disease and diabetes.  
Aims: 
• To review physical, social, psychological, and pharmacological factors in inpatients with diabetes 
and cardiovascular disease to determine if they affect care integration measured by readmission and 
follow up questionnaires.  
• To assess short term care integration, through 1-month follow up questionnaires and readmission 
within 30 days. 
• To assess long term care integration, through 6-month follow up questionnaires and readmission data 
for the duration of the project. 
• To assess prescribing of potentially inappropriate medications in the study population 
• To identify, within the population of interest, if there is a subset of individuals who are at greater risk 
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Participants were prospectively enrolled over the study period from the Royal Adelaide Hospital. The 
population of interest was patients with Diabetes Mellitus and any form of cardiovascular disease aged 50 or 
older, discharged alive and not to high level residential aged care. Other inclusion criteria were the ability to 
provide written informed consent and comply with study procedures as well as having sufficient English 
language skills to answer study questions. Patients were excluded if they had palliative intent, delirium or 
other cognitive impairment which would interfere with consent and study assessments, were admitted from 
or likely to be discharged to high level residential aged care facilities or those whose clinical team felt should 
not be approached. Patients were identified through Allscripts Sunrise Electronic Health Record (Sunrise) 
(Allscripts, Chicago, IL) by filtering for glycated haemoglobin (HbA1c) blood tests to identify diabetic 
patients. Medical records were checked for age, a diagnosis of any form of cardiovascular disease and their 
residential status. A nurse involved in their care was then approached to confirm eligibility. Pharmacists on 
wards of interest were also involved in identifying and recruiting participants. Once deemed eligible, patients 
were approached, informed about the study and invited to participate. 
 
Data Collection 
Baseline data were collected after consent and during the initial admission where possible. If participants 
were discharged before data collection was completed, the remaining assessments were completed over the 
phone or sent in the mail. Participants were asked how many general practitioners, pharmacies, and 
specialists they had seen in the last 12 months and whether they had received a Home Medicines Review or 
Chronic Disease Care Plan. Frailty was assessed using a modified Reported Edmonton Frail Scale as 
described by Hilmer et al22, as well as the Clinical Frailty Scale and Barthel’s Index. Questions and 
assessments were completed verbally. Participants were then given the 21-item Depression Anxiety and 
Stress Scales (DASS21)23 and the Multidimensional Health Locus of Control to assess which factors 
participants believe control their health24; these were left with participants to complete in their own time. 
Comorbidities were collected from Sunrise or case notes, totalled and analysed according to the Charlson 
Comorbidity Index.25 Open Architecture Clinical Information System (OACIS) v 7.1.0.106 (OACIS, Telus 
Health, Longueuil, Canada) was used to gather latest blood test results, and final discharge dates to 
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determine length of stay (LOS). When participants were transferred to another hospital, rehabilitation 
facility, or Hospital at Home, their discharge from these services was recorded as their final discharge date 
but the time spent there was not included in the LOS.  
 
Medication Assessments  
The total number of regular discharge medicines and administrations per day were counted, excluding 
medications which were prescribed for a short period after discharge, or to be taken as required. 
Polypharmacy was considered ≥5 regular medications and ≥10 regular medications was labelled as 
hyperpolypharmacy as these are common in the literature.6, 7, 26 Both the 201527 and 201928 updated 
American Geriatrics Society Beers Criteria were used to determine if participants were taking potentially 
inappropriate medications; medications which had recommendations in multiple categories were only 
counted once per participant. Where the Beers criteria recommended dose reductions but lacked clarity the 
Therapeutic Goods Administration (TGA) approved product information and Australian Medicines 
Handbook29 were used to determine whether the dose was appropriate. The Drug Burden Index (DBI) was 
calculated to assess anticholinergic and sedative burden30, and the Anticholinergic Risk Scale was applied to 
each medication list to assess anticholinergic load.31 These assessments have been widely used and validated 
to assess medication use in older persons.6, 26, 32, 33 
 
Outcome Measures  
The primary outcome measure was time to readmission; OACIS was used to determine if and when 
participants were readmitted, and all unplanned readmissions were included. Initially emergency department 
(ED) presentations were included as a readmission however after initial analyses it was decided to exclude 
emergency department presentations and re-analyse the data to make this outcome measure clearer. 
Secondary outcomes were readmission within 30 days and responses to follow up questionnaires. 
Participants were sent follow-up questionnaires 1-month and 6-months after discharge to assess their 
experiences of care integration in the primary healthcare system. Participants were asked “how confident are 
you in the purpose of taking each of your medications?” on a 5-point Likert scale from “not confident at all” 
to “completely confident”, similar to one described by Arinzechukwu et al.34 at 1 month. At 6 months 
participants were sent the 20-item Patient Assessment of Care for Chronic Conditions35, from which question 
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5 “over the past 6 months I was satisfied that my care was well organised” rated on a 5-point Likert scale 
from “none of the time” to “always” was analysed. For participants who were lost to follow up the censor 
date recorded was their last form of contact, either with follow up assessments or with the hospital through 
outpatient appointments, to avoid survivor bias.  
 
Statistical Analysis 
Data were analysed with SPSS version 25 (IBM Corp, Armonk NY, USA). The non-parametric one-sample-
Kolmogorov-Smirnov test was used to determine if data were normally distributed. To assess for differences 
between the group which were readmitted and those who were not several tests were used. Scale data which 
were not normally distributed were analysed by the non-parametric independent samples Mann-Whitney U 
test. Scale data which were normally distributed were analysed by the independent samples T-test and 
nominal and ordinal variables were analysed using a Chi-square test. Univariate survival analyses of time to 
readmission for were performed using a Kaplan-Meier analysis. The results of these Kaplan-Meier analyses 
which were significant or near significant (p<0.2) were used in a backward stepwise Cox Regression 
multivariate analysis for time to readmission and a multivariate binary Logistic Regression for readmission 
within 30 days.  
 
Ethical Considerations  
This study was approved by the Central Adelaide Local Health Network Human Research Ethics Committee 
reference number: R20190301. All participants gave written informed consent and were given a copy of their 
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Eligible and enquired about 
participating 
N = 150 
Declined to 
participate 
N = 33 
Consented 
N = 117 
Excluded after consent n = 4 
Discharged to nursing home (2) 
Died during admission (2) 
Withdrawn n = 4 
Withdrawn only from follow up 
questionnaires n = 4 
Lost to follow up n = 5 
Analysed (including ED) 
N = 100 
Analysed (excluding ED) 
N = 104 
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Results  
Including Emergency Department Visits 
A total of 117 participants were recruited, after exclusions and withdrawals, data for 100 participants were 
analysed. 47% participants were readmitted during the study with 30% being within 30 days of discharge. 
The 1-month follow-up questionnaire was returned by 80% of participants and 28% completed the 6-month 
questionnaire. The baseline demographics and clinical characteristics of the study population are displayed in 
Table 1, scale variables are presented as median (Interquartile range (IQR)) and nominal and ordinal data as 
n (%). Statistical significance was set at p≤0.05.  
The median age was 68 (IQR 61.3, 77.0) and 33% were female. 75% of the index admissions were due to 
any complication of diabetes and the median length of stay was 7.5 days (IQR 4.0, 14.8). The cohort was 
highly multimorbid with the median number of conditions being 7 (IQR 5, 9.8), the median Charlson score 
was 3.0 (IQR 2.0, 5.0). None of the variables collected were significantly different between those readmitted 
during the study and those who were not. Individual comorbidities were also not found to have any 
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Table 1. Demographic and clinical characteristics of the study population split by readmitted and not 
readmitted. 
 Readmitted During 
Study 








Age at consent  
68.0 (64.0, 78.0) 
 
66.0 (60, 77.0) 
 
68.0 (61.3, 77.0) 
NS 
Gender, (n female (%)) 13.0 (27.7) 20.0 (37.7) 33 (33.0) NS 
Total number of 
comorbidities 
 
7.0 (5.0, 10.0) 
 
7.0 (5.0, 9.0) 
 
7.0 (5.0, 9.8) 
NS 
Charlson Comorbidity Index  
4.0 (2.0, 5.0) 
 
3.0 (2.0, 5.0) 
 
3.0 (2.0, 5.0) 
NS 
Location, (n rural (%)) 13.0 (27.7) 19.0 (35.8) 32 (32.0) NS 
















































*n = 88 
NS 
Number of GP practices 1.0 (1.0, 2.0) 
*n = 42 
1.0 (1.0, 1.0) 
*n = 48 
1.0 (1.0, 2.0) 
*n = 90 
NS 
Number of pharmacies 1.0 (1.0, 2.0) 
*n = 43 
1.0 (1.0, 2.0) 
*n = 49 
1.0 (1.0, 2.0) 
*n = 92 
NS 
Number of specialists 1.0 (0.0, 4.0) 
*n = 43 
1.0 (0.0, 3.0) 
*n = 48 
1.0 (0.0, 3.0) 
*n= 91 
NS 
Initial LOS  
7.0 (4.0, 19.0) 
 
8.0 (4.0, 14.5) 
 
7.5 (4.0, 14.8) 
NS 
Home Medicines Review 8.0 (18.6) 
*n = 41 
8.0 (16.3) 
*n = 49 
16 (17.4) 
*n = 92 
NS 
Chronic Disease Care plan 18.0 (41.9) 
*n = 43 
19.0 (38.8) 
*n = 49 
37 (40.2) 
*n = 92 
NS 
BMI 28.3 (25.7, 34.7) 
*n = 40 
29.5 (25.9, 36.2) 
*n = 48 
28.9 (25.8, 35.2) 
*n = 88 
NS 
HbA1c 7.5 (6.4, 9.4) 
*n = 43 
7.9 (7.3, 9.5) 
*n = 51 
7.6 (6.9, 9.5) 
*n = 94 
NS 
Creatinine 91.0 (78.0, 179.0) 
 
92.5 (62.3, 129.8) 
*n = 52 
92.0 (66.0, 153.0) 
*n = 99 
NS 





LDL 1.5 (1.0, 2.1) 
*n = 34 
1.5 (1.0, 1.9) 
*n = 38 
1.5 (1.0, 2.0) 
*n = 72 
NS 
HDL 1.0 (0.7, 1.3) 
*n = 34 
0.9 (0.7, 1.3) 
*n = 38 
0.9 (0.7, 1.3) 
*n = 73 
NS 
eGFR 61.0 (35.0, 89.0) 62.0 (39.0, 90.0) 61.5 (36.5, 90.0) NS 
Creatinine Clearance 67.9 (41.3, 109.3) 
*n = 43 
84.6 (40.6, 139.3) 
*n = 48 
77.8 (41.3, 119.3) 
*n = 91 
NS 
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Medication details are summarised in table 2; participants were discharged with a median of 10 regular 
medications (IQR 7, 12), 97% had polypharmacy and 52% had hyperpolypharmacy. The median scores for 
both versions of the Beers Criteria were 0 (IQR 0.0, 1.0) similarly, the median ARS score was 0 (IQR 0, 0). 
Polypharmacy was assessed at baseline as part of the Edmonton frailty scale and more participants reported 
taking less than 5 medications than was observed when totalling discharge medications, as such, ‘new 
polypharmacy’ was observed in 17.5% of participants. However, this had no observed effect on readmission.  
 
Table 2. Summary of medication details and assessments split by readmitted and not readmitted.  
 Readmitted During 
Study 









Number of discharge medicines  
10.0 (7.0, 12.0) 
 





Number of administrations per 
day 
 








Polypharmacy 45.0 (95.7) 52.0 (98.1) 97 (97.0) NS 
Hyperpolypharmacy 25.0 (53.2) 27.0 (50.9) 52 (52.0) NS 





*n = 97 
NS 
Number of 2019 Beers drugs  
0.0 (0.0, 1.0) 
 
0.0 (0.0, 1.0) 
 
0.0 (0.0, 1.0) 
NS 
Number of 2015 Beers drugs  
0.0 (0.0, 1.0) 
 
0.0 (0.0, 1.0) 
 
0.0 (0.0, 1.0) 
NS 
Anticholinergic Risk Scale  
0.0 (0.0, 0.0) 
 
0.0 (0.0, 0.0) 
 
0.0 (0.0, 0.0) 
NS 
 
The results of the frailty and psychological assessments are summarised in table 3. The cognition element of 
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Table 3. Summary of frailty and psychological assessments split by readmitted and not readmitted. 
 Readmitted During 
Study 













6.0 (5.0, 9.0) 
6.0 (5.0, 7.0) 
 
7.0 (5.0, 8.0) 
5.0 (4.0, 7.0) 
 
7.0 (5.0, 8.0) 
5.5 (4.0, 7.0) 
NS 
Barthel’s Index 95.0 (83.8, 100.0) 
 
*n = 46 
95.0 (83.8, 
100.0) 
*n = 50 
95.0 (85.0, 
100.0) 
*n = 96 
NS 
Clinical Frailty Score 4.0 (4.0, 5.0) 
*n = 44 
4.0 (3.0, 5.0) 
*n = 50 
4.0 (3.0, 5.0) 
*n = 94 
NS 
DASS21 Depression 2.0 (1.0, 5.0) 
*n = 35 
4.0 (2.0, 7.5) 
*n = 41 
3.0 (1.0, 6.0) 
*n = 76 
NS 
DASS21 Anxiety 4.0 (2.0, 7.0) 
*n = 35 
5.0 (2.5, 7.0) 
*n = 41 
4.0 (2.0, 7.0) 
*n = 76 
NS 
DASS21 Stress 2.0 (0.0, 6.0) 
*n = 35 
4.0 (2.0, 9.0) 
*n = 41 
4.0 (1.0, 8.0) 
*n = 76 
NS 
LoC Internal 24.0 (18.8, 29.3) 
*n = 34 
25.0 (23.0, 29.3) 
*n = 42 
25.0 (21.0, 29.0) 
*n = 76 
NS 
LoC Chance 17.5 (12.0, 23.3) 
*n = 34 
17.0 (13.8, 24.0) 
*n = 42 
17.0 (13.3, 24.0) 
*n = 76 
NS 
LoC Powerful Others  23.5 (16.8, 27.3) 
*n = 34 
24 (21.8, 28.3) 
*n = 42 
24.0 (19.3, 28.0) 
*n = 76 
NS 
 
Univariate Kaplan-Meier survival analyses of time to readmission produced some significant results. Figure 
2 displays the overall survival function for time to readmission. 
Figure 2. Kaplan Meier curve showing the time to readmission over the study period. 
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Kaplan-Meier analyses of key variables revealed that the stress subscale on the DASS21 (figure 3) 
assessment was significantly associated with time to readmission (p = 0.41).  
 
Figure 3. Kaplan Meier curve showing the time to readmission for tertile scores of the DASS stress subscale 
n = 76, p = 0.041. 
 
The curve shown in figure 3 indicated that a score of 2 or less, or the least amount of stress, was significantly 
associated with a shorter readmission free survival time. No other variables were significantly associated 
with time to readmission in Kaplan-Meier analyses however several variables were near significant (p<0.2). 








P = 0.041 
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Table 4 Results of the multivariate Cox Regression analysis of time to readmission for n=79.  
 Hazard Ratio 95% Confidence Interval P Value 
Hypertension 2.292 1.004 – 5.231 0.049 
Rural 0.473 0.234 – 0.954 0.037 
1-Month Purpose 
of Medications 
0.727 0.540 – 0.979 0.036 
Functional 
Performance 
1.502 1.098 – 2.054 0.011 
This model suggests when these factors are present together, hypertension and lower functional performance 
as assessed by the Edmonton Scale are associated with an increased hazard of readmission whereas living 
rurally and higher confidence in medication purpose have a smaller risk. 
 
Excluding Emergency Department Visits  
When emergency department visits were excluded from readmissions the percentage of participants 
experiencing an event dropped to 36% with 19% of those occurring within a month (refer to figure 4). 
However, differences between readmitted and not readmitted participants were still insignificant. 
Figure 4. Kaplan Meier curve showing the time to readmission over the study period once emergency 
department visits were excluded. 
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Participants’ confidence in the purpose of taking their medications 1 month after discharge was significantly 
associated with time to readmission (figure 5) although the group ‘not confident at all’ had only 2 
participants. In order to have more even groups, it was split into a binary response of ‘completely confident’ 
or ‘not completely confident’ however, this was found to be insignificant.  
 
Figure 5 Kaplan Meier curve showing the time to readmission based on the responses to the 1-month follow 
up questionnaire n=80, p˂0.001. 
 
Neither the multivariate Cox Regression analysis for time to readmission nor the multivariate binary Logistic 
Regression for readmission within 30 days produced significant results once emergency department visits 
were excluded as readmissions. 
 
Discussion 
The percentage of participants with polypharmacy in this study was 97% and extremely high; a study 
investigating polypharmacy in inpatients ≥65 years of age reported 60% of participants with polypharmacy.6 
Furthermore, analyses of polypharmacy in Australians aged ≥70 and ≥50 reported polypharmacy in 36.1%36 
and 43.3%37 respectively. These studies did not solely investigate diabetics which may contribute to the 
differences as the prevalence of polypharmacy has been shown to be higher in diabetics.26 However this 
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study still observed higher rates of polypharmacy than other diabetic investigations.10 This large prevalence 
of polypharmacy meant there was insufficient data to assess the hypothesis as the non-polypharmacy group 
was too small. This is a limitation of the study and may be overcome by pre-screening participants based on 
medication numbers in future. However, the concept of new polypharmacy observed here and contradictory 
results from Best et al. of decreased polypharmacy between admission and discharge6 also need to be 
considered if this route is taken. Decreasing the age of inclusion may also help with heterogeneity of the 
study population however then the medication assessments used would be less valid.28, 30, 31  
 
Although large in quantity, the medications prescribed were largely appropriate as determined by the low 
median scores for the Beers Criteria, ARS and DBI which is a positive result. These scores were also lower 
than reported in the literature for similar studies6, 7, 26 and it has also been shown that the Beers criteria scores 
lower in diabetics compared to non-diabetics.26 Medications may still play a role in readmission as 
participants confidence in the purpose of taking their medications was shown to be significantly associated 
with time to readmission. However, this may be due to chance alone given the small number of participants 
reporting ‘not confident at all’ and this research should be repeated to validate this finding.  
 
The lack of significant findings may be due to how the primary outcome was measured. Similar studies have 
included emergency department visits as readmissions18 whereas others have not specified7. In this study ED 
visits likely provided noise around the outcome of readmissions yet removing them may have made the 
signal of readmission too weak. The readmission rate of 47% and 30% within 30 days is slightly higher than 
other studies however once emergency department visits were removed the rate of 19% within 30-days is 
comparable with the literature which ranges from 16-24.6%.7, 14, 15, 19 However these studies also reported 
larger sample sizes. Readmissions were collected from OACIS which only includes data for public hospitals, 
therefore, there are potentially other readmissions that were missed which presents a flaw in the data. The 
stress subscale of the DASS21 was found to be significantly associated with time to readmission. A study 
investigating the DASS21 in elderly diabetic patients found stress to be predictive of readmission.38 This 
does not support this study which showed lower rates of stress significantly associated with time to 
readmission. However, Alavi et al. reported a mean stress score of 19.2738 which was much higher than the 
median score of 4.0 reported here and may explain these conflicting results. 
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The results of the multivariate analysis presented in table 4 are mostly consistent with the literature. 
Hypertension has been shown to be a risk factor for readmission in cardiovascular patients39 whereas in 
diabetic patients it was associated with a reduction in the probability of 30-day readmission.7  Sukumar et al. 
found that rural patients are hospitalised less for falls but were more likely to be readmitted within 28-days 
for than metropolitan residents.40 The Australian Institute of Health and Welfare reported people in very 
remote areas needing almost twice as many hospitalisations that residents of major cities.41 These findings 
are not reflected in the multivariate model which indicates rural participants having a lower hazard of 
readmission. This is discrepancy is likely due to an inability to collect readmission data for rural participants 
as rural hospitals are not listed on OACIS. Future studies may benefit from excluding rural participants to 
avoid this. A study which investigated student pharmacists providing medication reconciliation showed those 
who received the service had higher confidence in the purpose of their medications and lower readmissions 
after 60 days.34 This supports the findings that for every one-point increase in confidence in medication 
purpose participants were almost a third less likely to be readmitted (hazard ratio 0.727, p=0.036). Lastly 
there is limited data for the individual components of the Edmonton Scale however, a study which used the 
same modification of the Reported Edmonton Frailty Scale (REFS) as discussed here, found the odds of 
readmission increased by 1.12 per one unit increase in the REFS.42 Similarly it was found that the greater the 
number of functional deficits participants had a hazard ratio of 1.502 for time to readmission (p=0.011). 
These results are useful but given the limitations of the data further research is required. 
 
A strength of this study was its prospective design although, its small sample size and single location mean 
the generalisability is low. The time frame and design of the study meant that participants had varying 
lengths of follow up which may have contributed to signal issues with readmission as an outcome measure. 
This should be rectified in future studies by allowing for a longer follow-up period so that more similar 
amounts of data are available for all participants. A longer study would also allow for inclusion of drug-
related readmissions as an outcome measure as the coding for this data means the information is not 
available at the time of readmission. Another positive of this investigation is that it allowed for the creation 
of a rich data set of a complex population which can be analysed with different focuses for future studies, 
however, the assessments had varying levels of compliance meaning the sample size for some is quite small. 
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Conclusion 
The level of polypharmacy observed was higher than the general Australian population36, 37 and other 
diabetic populations.10 The data collected were biased towards more complicated patients and were 
insufficient to investigate the hypothesis, however the results of the study are still useful and comparable 
with the literature. This research provides valuable insight into the levels of polypharmacy and prescription 
of potentially inappropriate medications in the sample population. The data is also useful for understanding 
readmission rates and presentations to emergency departments at public hospitals in this population. The 
multivariate model for time to readmission needs further research, however, may prove useful for targeting 
care integration interventions. There were several limitations with this investigation however these can be 
overcome with improved study design in future research which is necessary given the complexity of the 
population of interest. 
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